biostudies-literatureAltshuler PJAmerican Liver FoundationNational Institutes of HealthNIGMS NIH HHS623-635https://www.ebi.ac.uk/biostudies/studies/S-EPMC10152802biostudies-literatureUnknown28(4)The increasing prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) affects both recipient and donor populations in liver transplantation. Presently, it is unclear whether transplantation of macrosteatotic allografts is affected by the metabolic milieu of liver transplant recipients. This study investigates fatty liver disease at the intersection of donor and recipient. A retrospective review of the Organ Procurement and Transplantation database identified 5167 NASH and 26,289 non-NASH transplant recipients who received transplants from January 1, 2004, to June 12, 2020. A total of 12,569 donors had allografts with no macrosteatosis (<5%), 16,140 had mild macrosteatosis (5%-29%), and 2747 had moderate to severe macrosteatosis (≥30%). Comparing reciLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyEvaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis.PMC10152802T32 GM008562T32GM008562Shah APGlorioso JRamirez CBZhan TAltshuler PJBodzin ASMaley WRFrank AMShaheen ODang HRios Diaz AfalseEvaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis.The increasing prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) affects both recipient and donor populations in liver transplantation. Presently, it is unclear whether transplantation of macrosteatotic allografts is affected by the metabolic milieu of liver transplant recipients. This study investigates fatty liver disease at the intersection of donor and recipient. A retrospective review of the Organ Procurement and Transplantation database identified 5167 NASH and 26,289 non-NASH transplant recipients who received transplants from January 1, 2004, to June 12, 2020. A total of 12,569 donors had allografts with no macrosteatosis (<5%), 16,140 had mild macrosteatosis (5%-29%), and 2747 had moderate to severe macrosteatosis (≥30%). Comparing reci2022-01-01T00:00:00Z2022 Apr2025-04-04T00:04:00.387Z2025-04-04T00:04:00.387ZS-EPMC101528023456493110.1002/lt.26313